| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1352 | 2021 |
| PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial F Lordick, K Ott, BJ Krause, WA Weber, K Becker, HJ Stein, S Lorenzen, ... The lancet oncology 8 (9), 797-805, 2007 | 946 | 2007 |
| 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, F Ceci, S Cho, F Giesel, ... European journal of nuclear medicine and molecular imaging 44, 1014-1024, 2017 | 755 | 2017 |
| Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial WP Fendler, J Calais, M Eiber, RR Flavell, A Mishoe, FY Feng, ... JAMA oncology 5 (6), 856-863, 2019 | 581 | 2019 |
| Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction K Ott, WA Weber, F Lordick, K Becker, R Busch, K Herrmann, H Wieder, ... Journal of Clinical Oncology 24 (29), 4692-4698, 2006 | 565 | 2006 |
| Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ... Journal of Nuclear Medicine 59 (3), 469-478, 2018 | 479 | 2018 |
| The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer BJ Krause, M Souvatzoglou, M Tuncel, K Herrmann, AK Buck, C Praus, ... European journal of nuclear medicine and molecular imaging 35, 18-23, 2008 | 426 | 2008 |
| Spect/ct AK Buck, S Nekolla, S Ziegler, A Beer, BJ Krause, K Herrmann, ... Journal of Nuclear Medicine 49 (8), 1305-1319, 2008 | 425 | 2008 |
| EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) C Kratochwil, WP Fendler, M Eiber, R Baum, MF Bozkurt, J Czernin, ... European journal of nuclear medicine and molecular imaging 46, 2536-2544, 2019 | 326 | 2019 |
| Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors TA Hope, EK Bergsland, MF Bozkurt, M Graham, AP Heaney, K Herrmann, ... Journal of Nuclear Medicine 59 (1), 66-74, 2018 | 283 | 2018 |
| Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR “Train the trainers” course AK Scheel, WA Schmidt, KGA Hermann, GA Bruyn, MA D’Agostino, ... Annals of the rheumatic diseases 64 (7), 1043-1049, 2005 | 268 | 2005 |
| 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage … J Calais, J Czernin, M Cao, AU Kishan, JV Hegde, N Shaverdian, ... Journal of Nuclear Medicine 59 (2), 230-237, 2018 | 267 | 2018 |
| Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches AK Buck, K Herrmann, T Stargardt, T Dechow, BJ Krause, J Schreyögg Journal of nuclear medicine technology 38 (1), 6-17, 2010 | 265 | 2010 |
| First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary … K Herrmann, M Schottelius, C Lapa, T Osl, A Poschenrieder, H Hänscheid, ... Journal of nuclear medicine 57 (2), 248-251, 2016 | 251 | 2016 |
| PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data S Fanti, S Minozzi, P Castellucci, S Balduzzi, K Herrmann, BJ Krause, ... European journal of nuclear medicine and molecular imaging 43, 55-69, 2016 | 240 | 2016 |
| E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ... European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021 | 235 | 2021 |
| Comparison of integrin αvβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG AJ Beer, S Lorenzen, S Metz, K Herrmann, P Watzlowik, HJ Wester, ... Journal of Nuclear Medicine 49 (1), 22-29, 2008 | 230 | 2008 |
| 2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical … H Schöder, K Herrmann, M Gönen, H Hricak, S Eberhard, P Scardino, ... Clinical cancer research 11 (13), 4761-4769, 2005 | 227 | 2005 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 224 | 2019 |
| Prostate-specific membrane antigen ligands for imaging and therapy M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ... Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017 | 214 | 2017 |
